ObsEva
ObsEva [NASDAQ: OBSV; SIX: OBSN] is a Swiss-based, specialty biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine. ObsEva’s main focus is on therapies for preterm labor. ObsEva was founded in 2012 by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a clinician specialized in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. He was previously Co-Founder and CEO of PregLem. André Chollet is a medicinal and pharmaceutical chemist with over 30 years of experience gained in diverse roles within the biopharmaceutical industry, including at Biogen, GSK and Merck Serono.
Sector
Biopharmaceuticals
Strategy
Status
Exit
Website
www.obseva.com
Related News
ObsEva SA Announces Pricing of Initial Public Offering
ObsEva Expands Leadership Team and Board of Directors with Industry Veterans
ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI
ObsEva Closes CHF 60 (USD 60) Million in Series B Financing
ObsEva Appoints Elke Bestel as Chief Medical Officer and Jean-Pierre Gotteland as Chief Scientific Officer
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.